Krystal Biotech Revenue and Competitors

Claim your profile

Location

#4992

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Krystal Biotech's estimated annual revenue is currently $21.5M per year.(i)
  • Krystal Biotech's estimated revenue per employee is $119,033
  • Krystal Biotech's total funding is $386M.

Employee Data

  • Krystal Biotech has 181 Employees.(i)
  • Krystal Biotech grew their employee count by 65% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M10-33%N/AN/A
#2
$3.4M2210%N/AN/A
#3
$4.3M673%N/AN/A
#4
$5.4M3525%N/AN/A
#5
$8.4M5413%N/AN/A
#6
$2.2M28-32%$157.5MN/A
#7
$2M138%N/AN/A
#8
$29.5M19012%N/AN/A
#9
$3.7M24-17%N/AN/A
#10
$58.1M375-2%N/AN/A

Krystal Biotech, Inc. is using gene therapy to develop effective and novel treatments for skin diseases. Our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. We work to accomplish that through scientific innovation, operational excellence and believe that ?nature operates in the shortest way possible?. (Aristotle)

keywords:N/A

$386M

Total Funding

181

Number of Employees

$21.5M

Revenue (est)

65%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Krystal Biotech News

2022-04-19 - Reviewing Krystal Biotech (NASDAQ:KRYS) and iTeos ...

Get Krystal Biotech alerts: This table compares Krystal Biotech and iTeos Therapeutics' net margins, return on equity and return on assets.

2022-04-06 - Krystal Biotech Announces Home Dosing in B-VEC Open ...

PITTSBURGH, April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies,...

2022-03-22 - Krystal Biotech Announces Publication of Phase 1 and 2 ...

Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine.

2021-10-19 - Krystal Biotech : Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis

PITTSBURGH, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a redosable gene therapy can ...

2021-10-14 - Krystal Biotech : Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT

PITTSBURGH, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second genetic pulmonary disease candidate KB408, for the treatment ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$53.8M18128%N/A
#2
$19.9M18116%N/A
#3
$34.5M182-3%N/A
#4
$41M1828%N/A
#5
$54.4M18311%N/A